Our scientists have developed a new non-invasive approach to diagnosing cancer at an early stage.

D. Shcherbo, a senior researcher at the Research Institute of Translational Medicine, spoke about this. The method is based on the analysis of circulating DNA from human blood and uses a new ssDNA end profiling method. The method was tested on 175 samples of healthy people, colorectal cancer patients and kidney cancer patients. The average pathogenicity score of samples from oncological patients was 0.83, from healthy donors — 0.28. The scientists reported on the results at major international conferences: the Congress of the European Society for Medical Oncology (ESMO Congress 2021) and the 54th Congress of the European Society of Human Genetics (ESHG Conference 2021).